Eliav Barr
Known title: DirectorCIK: 0001940521
Associated companies
Transaction History
| VCYT | ▲ Buy | Grant | 5,272 | $0 | 6/11/2026 | View on chart |
| VCYT | ▲ Buy | Grant | 9,321 | $0 | 6/18/2025 | View on chart |
| VCYT | ▲ Buy | Grant | 11,473 | $0 | 6/13/2024 | View on chart |
| VCYT | ▲ Buy | Grant | 9,674 | $0 | 6/9/2023 | View on chart |
| VCYT | ▲ Buy | Grant | 20,721 | $0 | 8/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise
Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise. Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.